A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Adimmune Corporation
- 12 Jul 2018 Status changed from recruiting to completed.
- 21 Jan 2013 New trial record